1430745-84-8

Basic information

• Product Name: (1R,3s,5S)-tert-butyl 3-((1r,4R)-4-(2-methyl-6-(pyridazin-4-yl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate
• Synonyms: (1R,3s,5S)-tert-butyl 3-((1r,4R)-4-(2-methyl-6-(pyridazin-4-yl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate
• CAS NO: 1430745-84-8
• Molecular Weight: 494.634
• Mol File: 1430745-84-8.mol

Chemical Properties

• CAS DataBase Reference: (1R,3s,5S)-tert-butyl 3-((1r,4R)-4-(2-methyl-6-(pyridazin-4-yl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,3s,5S)-tert-butyl 3-((1r,4R)-4-(2-methyl-6-(pyridazin-4-yl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate(1430745-84-8)
• EPA Substance Registry System: (1R,3s,5S)-tert-butyl 3-((1r,4R)-4-(2-methyl-6-(pyridazin-4-yl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate(1430745-84-8)

Safety Data

• Hazardous Substances Data: 1430745-84-8(Hazardous Substances Data)

Upstream product

• 1430746-07-8 (1R,3s,5S)-tert-butyl 3-(4-(benzyloxy)phenoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 103-16-2 4-Benzyloxyphenol 
• 143557-91-9 (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1430746-24-9 (1R,3s,5S)-tert-butyl 3-((1s,4S)-4-hydroxycyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1430746-13-6 (1,3s,5S)-tert-btyl 3-((1,4R)4-(6-bromo-2-methylpyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 194865-89-9 4-(tributylstannanyl)pyridazine 
• 1430746-08-9 (1R,3s,5S)-tert-butyl 3-(4-hydroxyphenoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 

Relevant articles and documents

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof,that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.